Biomedical Photonic Imaging, Faculty of Science and Technology, Mira Institute of Biomedical Technology and Technical Medicine, University of Twente, Postbox 217, 7500AE Enschede, The Netherlands.
Langmuir. 2010 Apr 6;26(7):5050-5. doi: 10.1021/la100166f.
Recent reports [Smith and Korgel Langmuir 2008, 24, 644-649 and Smith et al. Langmuir 2009, 25, 9518-9524] have implicated certain hexadecyltrimethylammonium bromide (CTAB) products with iodide impurities, in the failure of a seed-mediated, silver and surfactant-assisted growth protocol, to produce gold nanorods. We used two of the three "suspect" CTAB products and a "good" CTAB product in the protocol, varying silver nitrate solutions in the growth solutions. We obtained excellent gold nanorod samples as witnessed in signature longitudinal plasmon peaks in optical extinction spectra, which we substantiated using electron microscopy. Analysis of these samples using inductively coupled plasma mass spectroscopy (ICP-MS) failed to detect iodide. We subsequently learnt from discussions with Smith et al. that different lot numbers within the same product had been analyzed by our respective laboratories. We can conclude that iodide impurities can vary significantly from lot to lot within a product, to such an extent that there is no guarantee that gold nanorods can be synthesized with one or other CTAB product. Conversely, labeling a CTAB product, identified by a product number or supplier name, as one whose use precludes the formation of nanorods, is also hasty.
最近的报告[Smith 和 Korgel Langmuir 2008, 24, 644-649 和 Smith 等人 Langmuir 2009, 25, 9518-9524]表明,某些十六烷基三甲基溴化铵(CTAB)产品中含有碘化物杂质,这导致了一种基于种子介导、银和表面活性剂辅助生长的方案无法制备金纳米棒。我们在该方案中使用了三种“可疑”CTAB 产品中的两种和一种“良好”CTAB 产品,并在生长溶液中改变了硝酸银溶液的浓度。我们获得了出色的金纳米棒样品,这可以从光学消光谱中的特征纵向等离子体峰中得到证明,我们使用电子显微镜对其进行了证实。使用电感耦合等离子体质谱(ICP-MS)对这些样品进行分析未能检测到碘化物。随后,我们从与 Smith 等人的讨论中了解到,我们各自的实验室对同一产品中的不同批次进行了分析。我们可以得出结论,碘化物杂质在产品中的批次之间可能存在显著差异,以至于不能保证可以使用一种或另一种 CTAB 产品来合成金纳米棒。相反,将 CTAB 产品(通过产品编号或供应商名称进行标识)标记为不能形成纳米棒的产品也是草率的。